04.15.26 -- What It Takes to Maximize Your Biologic's Chances of Clinical Success

Preclinical failure stems from misaligned strategy, developability, and execution; early risk ID, integrated planning, and strong data move biological candidates efficiently to clinic.

Developability assessments flag early risks in stability, manufacturability, and immunogenicity, helping teams focus on candidates most likely to succeed clinically and commercially.

Process changes in biologics manufacturing are inevitable, but how you manage comparability can make or break a program. When teams treat comparability as a formality, subtle shifts in product characteristics can go undetected until it's too late. This article outlines a holistic, risk-based approach that combines risk assessment, advanced analytics, and regulatory expectations that keep biologics safe, effective, and compliant.

Process development bridges early discovery and clinical manufacturing, reducing risk, improving scalability, and aligning biologic programs with regulatory and commercial success from the start.

Watch Erika Kovacs, Senior Director of Bioassay, as she discusses critical considerations for developing stage-appropriate bioassays that streamline complex biologics and bioconjugates to IND and beyond.

Uncover how rapid, multidimensional assessments that optimize stability, manufacturability, and clinical success potential have been able to accelerate lead candidate selection.

Selecting the right biologics CDMO requires evaluating technical depth, scalability, quality systems, and partnership fit to reduce risk and support long‑term development success.